摘要
Abstract
OBJECTIVE:To stndy the clinical efficacy and safety of somatostatin combined with pantoprazole sodium in the treatment of severe acute pancreatitis(SAP). METHODS:By retrospective analysis,98 patients with SAP were divided into control group and observation group by the different treatment. All patients were treated by routine treatment of SAP. Based on it,patients in control group were given Pantoprazole sodium for injection 40 mg adding into 0.9% sodium chloride injection 100 ml,iv,twice a day;patients in observation group were given Somatostatin for injection 3 mg adding into 0.9% sodium chloride injection 100 ml based on the treatment of control group,by micro intravenous continuous intravenous infusion,0.25 mg/h,twice a day.Both cours-es were 7 d. The clinical data was observed,including clinical efficacy,improvement time of signs and symptoms(remission time of stomachache,recovery time of gastrointestinal function,withdrawal time of ventilator) and tumor necrosis factor-α(TNF-α), high-sensitivity C-reactive protein (hs-CRP),interleukin-8 (IL-8) levels and the incidence of adverse reactions before and after treatment. RESULTS:The total effective rate in observation group was significantly higher than control group,and the improve-ment time of signs and symptoms was significantly shorter than control group,with significant differences(P<0.05). After treat-ment,the inflammatory cytokine levels in 2 groups were significantly lower than before,and observation group was lower than con-trol group,with significant differences(P<0.05). The incidence of adverse reactions in observation group was significantly lower than control group,with significant difference(P<0.05). CONCLUSIONS:Based on the routine treatment,somatostatin combined with pantoprazole sodium has better efficacy than only pantoprazole sodium,with better safety.关键词
生长抑素/泮托拉唑钠/重症急性胰腺炎/疗效/安全性Key words
Somatostatin/Pantoprazole sodium/Severe acute pancreatitis/Efficacy/Safety分类
医药卫生
